Why Explore Vaccines After Pancreatic Cancer Surgery?

This article provides a roundup of recent clinical trial updates and FDA regulatory news regarding oncology treatments, specifically focusing on neuroendocrine tumors and various cancers. It highlights advancements in immunotherapy and targeted drug therapies discussed by medical experts.
Why it matters
These updates are critical for oncologists and patients tracking the latest developments in cancer research and potential new treatment pathways.
Why Explore Vaccines After Pancreatic Cancer Surgery? | Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Dr Trikalinos on Cabozantinib in Functional and Nonfunctional NETs
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Dr Lewis on Cabozantinib and Time Toxicity in Neuroendocrine Tumors
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in